Skip to content
CleaStart with Clea
Australia’s clearer way into migraine care.See how Clea works
Start with Clea
All treatmentsAcute · Triptan

Sumatriptan

Sumatriptan is one option discussed in migraine care. Clea explains where it sits in the treatment landscape without recommending it for an individual person.

Checking review recordSource references are available below.
ROLE BY HEADACHE TYPE

Which patterns is this used for?

Frequency and symptoms can overlap: someone can have chronic migraine and vestibular symptoms, for example. Choose a label to explore usual roles, not to select a treatment for yourself.

General information, not personal medical advice. Some uses are off-label or supported by limited evidence. TGA approval, PBS eligibility and individual suitability differ. Do not start, stop or change treatment without your clinician or pharmacist.

Cluster headache (not migraine)

Acute · Established use

Only appropriate rapid-onset formulations are relevant to cluster attacks. Oral migraine tablets should not be assumed equivalent; confirm the formulation with a specialist.

NICE headache guideline: migraine and cluster headache

Use labels are an editorial guide to the cited sources, not a clinical recommendation or an independent clinical-review badge. Each profile retains its separate review status.

ROLE IN CARE

Where it fits

Migraine-specific acute treatment.

HOW IT IS USED

Administration

Oral, nasal or injectable forms depending product.

EVIDENCE

What we know

Triptans are established migraine-specific acute medicines.

AUSTRALIA

Access

Registered products are available in Australia.

HOW THE CLASS WORKS

Mechanism, in plain language.

Triptans act on serotonin 5-HT1B/1D receptors involved in trigeminovascular migraine signalling. That class mechanism is different from a general pain reliever, which is why triptans are considered migraine-specific acute treatments.

HOW TO JUDGE RESPONSE

Decide what “working” would mean.

For an acute treatment, useful questions include how reliably it improves the attack, how quickly function returns, whether symptoms recur, whether rescue treatment is still needed and how many days per month the medicine is used. Frequent use also matters because medication-overuse risk depends partly on medicine class and days of use.

WHAT TO ASK

Questions for the treatment conversation

  • What is the goal of using Sumatriptan in my migraine plan?
  • How will we decide whether it is helping enough to continue?
  • What side effects or warning signs should I know about?
  • Do any of my other medicines, conditions, pregnancy plans or allergies change the discussion?
  • What is the current Australian access pathway and likely cost for me?
WHAT TO TRACK

Give the next review better evidence.

Before and after a treatment change, record migraine-like days, total headache days, acute medicine days, severity and functional impact. If you notice side effects, record what happened and when rather than relying on memory at the next appointment.

Add to My Treatments
SAFETY

Suitability is individual.

Cardiovascular history, interactions and medication-overuse risk need clinician or pharmacist review.

Clea does not recommend, start, stop or change medicines. Discuss individual treatment decisions with your GP, neurologist, pharmacist or other treating clinician.

DRUGS.COM · EXTERNAL PATIENT REVIEWS

Read the right review category.

Original Drugs.com ratings use a 10-point scale. Read the source condition label and review count before drawing conclusions. “Migraine Prevention” is not a vestibular-only or episodic-only score, and a review category does not establish an approved indication.

Source links only. Clea has not imported ratings or review text. Republishing source scores requires permission; no licensed ratings feed is connected. Drugs.com is US-focused, so medicine names and approved uses may differ from Australia. Reviews are self-selected experiences, not comparative evidence of effectiveness.

CLEA COMMUNITY EXPERIENCE · NOT DRUGS.COM

Compare experiences from the same pattern.

People can report a migraine frequency and a symptom pattern separately, such as chronic plus vestibular. Labels are self-reported, not independently diagnosed or verified. Groups can overlap and cannot establish that one treatment works better than another.

Viewing: All migraine frequencies · All symptom patterns

Loading this group…

Small, self-selected groups are not clinical trials. Scores are perceived experiences and may reflect dose, treatment duration, other conditions and access as well as benefit. No personal identities are published here.

Log in to add your experience
SOURCES & CURRENT ACCESS

Check the original source.

Therapeutic Goods AdministrationPharmaceutical Benefits SchemeMigraine & Headache Australia drug directory

Keep your treatment story in one place.

Add treatments you have tried to My Clea, then use your history when preparing for your next appointment.

Open My Clea